
Basic Protective Measures Against COVID-19
COVID-19 is a new strain of the common cold that has been p...
COVID-19 is a new strain of the common cold that has been p...
Where is Ibritumomab Tiuxetan used?
Ibritumomab Tiuxetan is a monoclonal antibody that is used for the treatment of non-Hodgkin’s lymphoma. This drug is linked with a radioactive substance Yttrium-90 which is a manmade antibody that has a radioactive isotope attached to deliver radiation therapy to the lymphoma cells. The Food and Drug Administration has approved this prescription for medical use.
How does Ibritumomab Tiuxetan work?
A monoclonal antibody is a relatively new type of targeted cancer therapy. The antibody is an integral part of the immune system. Usually, the body makes antibodies in response to an antigen that has entered the body. This type of therapy is usually given only for cancer in which antigens have been identified already.
Ibritumomab Tiuxetan works by targeting the CD20 antigen on malignant and normal B-cells. On the other hand, it is more than a monoclonal antibody alone. The experts have shown, Yttrium-90 is linked to the antibody. Once the antibody is attached to the CD20 antigens, radiation is delivered straight to the targeted cells. It kills the targeted cells and cancer cells. This allows healthy B-cells to regenerate after treatment.
How is Ibritumomab Tiuxetan used?
What are the possible side effects of Ibritumomab Tiuxetan?
Infusion-related side effects:
Low red blood cell count:
Low platelet count:
It is important to let your doctor know right away if you experience any of these side effects.
What are the precautions in taking Ibritumomab Tiuxetan?